睿知中国医院研究地图
候选清单

正在招募肺癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

ClinicalTrials.gov 上登记的一项肺癌开放试验,由北京大学肿瘤医院牵头,本站收录的另外 7 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. After the last line of treatment before enrollment, progression is confirmed, and blood tests confirm c-Met amplification, or re-biopsy and genetic testing confirm c-Met amplification. Any of the following criteria define c-Met amplification.

    入选标准第 6 条

  3. Disease progression after prior EGFR-TKI therapy. Participants must meet both of the following 2 criteria:

    入选标准第 5 条

    Absolute neutrophil count ≥1.5×10⁹/L (without the use of growth factors within 7 days prior to the start of treatment);

    入选标准第 11 条

    Hemoglobin ≥90 g/L (without blood transfusion or use of growth factors within 7 days prior to the start of treatment);

    入选标准第 12 条

    Platelet count ≥75×10⁹/L (without blood transfusion or use of growth factors within 7 days prior to the start of treatment);

    入选标准第 13 条

    Serum lipase ≤1.5×ULN. 10. Men with reproductive potential and women of childbearing potential must agree to use effective contraception from the time of signing the informed consent form until 3 months after the last dose of the study drug. Women of childbearing potential must have a negative serum pregnancy test within ≤7 days prior to the first dose of the study drug. This does not apply to female subjects who have undergone sterilization or are postmenopausal.

    入选标准第 19 条

    Active infection requiring systemic antimicrobial therapy within 2 weeks prior to the first dose of the study drug;

    排除标准第 10 条

  4. Documented EGFR sensitive mutations (exon 19 deletion or exon 21 L858R mutation).

    入选标准第 4 条

    Serum total bilirubin ≤1.5×upper limit of normal (ULN);

    入选标准第 14 条

    Serum alanine aminotransferase and aspartate aminotransferase ≤3×ULN (for patients with liver metastases, both AST and ALT ≤5×ULN);

    入选标准第 15 条

    Creatinine clearance (Ccr) ≥60 mL/min.

    入选标准第 16 条

    International normalized ratio (INR) ≤1.5×ULN;

    入选标准第 17 条

  5. Presence of other malignancies (with the exception of any type of carcinoma in situ that has been completely resected, basal cell and squamous cell skin cancers, or other tumors/cancers that have been treated with curative intent and have been disease-free for at least 3 years).

    排除标准第 3 条

    Positive for anti-HIV, or positive for both anti-HCV and HCV-RNA, or positive for HBsAg with HBV-DNA ≥500 IU/mL

    排除标准第 7 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力;影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07087223,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Fully aware this study and voluntary to sign the informed consent form, and willing and able to comply with the study procedure.
  2. Aged ≥18 years, male or female.
  3. Patients with histologically or cytologically confirmed unresectable and non-suitable for radical surgery, or concurrent chemoradiotherapy , locally advanced or metastatic (stage IIIB, IIIC or IV) NSCLC;
  4. Documented EGFR sensitive mutations (exon 19 deletion or exon 21 L858R mutation).
  5. Disease progression after prior EGFR-TKI therapy. Participants must meet both of the following 2 criteria:
  6. After the last line of treatment before enrollment, progression is confirmed, and blood tests confirm c-Met amplification, or re-biopsy and genetic testing confirm c-Met amplification. Any of the following criteria define c-Met amplification.
  7. For tumor tissue samples, FISH detection shows GCN ≥5 and/or MET/CEP7 ≥2 (FISH results from local testing institutions/central laboratories are acceptable);
  8. Tissue (wax blocks from pleural effusion centrifugation, if quality-controlled) or blood NGS testing results confirm c-Met amplification with CN ≥2.3 (NGS results from local testing institutions/central laboratories are acceptable for both tissue and blood).
  9. ECOG performance status ≤1. 8. According to RECIST v1.1, the patient must have at least one target lesion as assessed by the investigator.
  10. Laboratory test results must meet the following criteria:
  11. Absolute neutrophil count ≥1.5×10⁹/L (without the use of growth factors within 7 days prior to the start of treatment);
  12. Hemoglobin ≥90 g/L (without blood transfusion or use of growth factors within 7 days prior to the start of treatment);
  13. Platelet count ≥75×10⁹/L (without blood transfusion or use of growth factors within 7 days prior to the start of treatment);
  14. Serum total bilirubin ≤1.5×upper limit of normal (ULN);
  15. Serum alanine aminotransferase and aspartate aminotransferase ≤3×ULN (for patients with liver metastases, both AST and ALT ≤5×ULN);
  16. Creatinine clearance (Ccr) ≥60 mL/min.
  17. International normalized ratio (INR) ≤1.5×ULN;
  18. Asymptomatic serum amylase ≤Grade 2 (NCI-CTCAE v5.0). For patients with Grade 2 serum amylase abnormalities at the start of the study, it must be confirmed that there are no signs and/or symptoms suggestive of pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal pancreatic imaging results);
  19. Serum lipase ≤1.5×ULN. 10. Men with reproductive potential and women of childbearing potential must agree to use effective contraception from the time of signing the informed consent form until 3 months after the last dose of the study drug. Women of childbearing potential must have a negative serum pregnancy test within ≤7 days prior to the first dose of the study drug. This does not apply to female subjects who have undergone sterilization or are postmenopausal.
  20. Expected survival ≥3 months.

排除标准:Exclusion Criteria:

  1. Patients with ALK fusion or ROS1 fusion.
  2. Patients with spinal cord compression, leptomeningeal metastasis, or symptomatic brain metastasis that requires an increase in steroid dosage to control central nervous system disease. Patients with symptomatic CNS metastases that have been controlled may be eligible for this trial.
  3. Presence of other malignancies (with the exception of any type of carcinoma in situ that has been completely resected, basal cell and squamous cell skin cancers, or other tumors/cancers that have been treated with curative intent and have been disease-free for at least 3 years).
  4. A history of anti-tumor treatment that meets any of the following criteria:
  5. Has any severe or uncontrolled systemic disease, including but not limited to:
  6. Uncontrolled hypertension, with the allowance for the initiation or adjustment of antihypertensive medications prior to screening;
  7. Positive for anti-HIV, or positive for both anti-HCV and HCV-RNA, or positive for HBsAg with HBV-DNA ≥500 IU/mL
  8. Active keratitis or ulcerative keratitis during the disease phase;
  9. Active tuberculosis;
  10. Active infection requiring systemic antimicrobial therapy within 2 weeks prior to the first dose of the study drug;
  11. Other severe medical conditions or psychiatric disorders, or laboratory abnormalities that, in the investigator's judgment, make the study drug unsuitable for the patient or affect protocol compliance; 8. Cardiac dysfunction and diseases that meet any of the following criteria:

引自 ClinicalTrials.gov, NCT07087223, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07087223,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07087223